Kevin Sek

2.4k total citations · 1 hit paper
11 papers, 1.3k citations indexed

About

Kevin Sek is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Kevin Sek has authored 11 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Kevin Sek's work include CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (4 papers). Kevin Sek is often cited by papers focused on CAR-T cell therapy research (7 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (4 papers). Kevin Sek collaborates with scholars based in Australia, Canada and United States. Kevin Sek's co-authors include Phillip K. Darcy, Paul A. Beavis, Melissa A. Henderson, Sherly Mardiana, Lauren Giuffrida, Lev M. Kats, Imran G. House, Junyun Lai, Emma V. Petley and Kirsten L. Todd and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Kevin Sek

10 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

2019 412 citations Imran G. House, Peter Savas et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin Sek Australia	8	935	749	419	205	179	11	1.3k
Sherly Mardiana Australia	12	1.2k 1.3×	824 1.1×	444 1.1×	306 1.5×	110 0.6×	13	1.5k
Junyun Lai Australia	13	819 0.9×	697 0.9×	336 0.8×	182 0.9×	38 0.2×	16	1.2k
Alexander J. Davenport Australia	12	859 0.9×	478 0.6×	273 0.7×	296 1.4×	74 0.4×	24	1.1k
Amanda X. Y. Chen Australia	6	607 0.6×	507 0.7×	260 0.6×	119 0.6×	36 0.2×	6	853
Emma V. Petley Australia	5	624 0.7×	511 0.7×	237 0.6×	121 0.6×	34 0.2×	7	854
Kirsten L. Todd Australia	5	585 0.6×	475 0.6×	230 0.5×	118 0.6×	34 0.2×	5	800
Swetha Anandhan United States	9	951 1.0×	899 1.2×	612 1.5×	152 0.7×	58 0.3×	13	1.8k
Po Y. Ho United States	7	391 0.4×	855 1.1×	337 0.8×	94 0.5×	128 0.7×	17	1.2k
Carmen S. Yong Australia	12	1.2k 1.2×	848 1.1×	455 1.1×	303 1.5×	11 0.1×	21	1.7k
McLane J. Watson United States	8	561 0.6×	791 1.1×	489 1.2×	164 0.8×	30 0.2×	10	1.4k

Countries citing papers authored by Kevin Sek

Since Specialization

Citations

This map shows the geographic impact of Kevin Sek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Sek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Sek more than expected).

Fields of papers citing papers by Kevin Sek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Sek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Sek. The network helps show where Kevin Sek may publish in the future.

Co-authorship network of co-authors of Kevin Sek

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Sek. A scholar is included among the top collaborators of Kevin Sek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Sek. Kevin Sek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Du, Xin, Pei Kee Goh, Chenkai Ma, et al.. (2025). Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models. Science Translational Medicine. 17(822). eadk0627–eadk0627.

2.

Wiede, Florian, Kun‐Hui Lu, Xin Du, et al.. (2021). PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discovery. 12(3). 752–773. 90 indexed citations

3.

Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2021). CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nature Communications. 12(1). 3236–3236. 150 indexed citations

4.

Giuffrida, Lauren, Kevin Sek, Melissa A. Henderson, et al.. (2020). IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. Molecular Therapy. 28(11). 2379–2393. 74 indexed citations

5.

Lai, Junyun, Sherly Mardiana, Imran G. House, et al.. (2020). Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nature Immunology. 21(8). 914–926. 159 indexed citations

6.

Sek, Kevin, Lev M. Kats, Phillip K. Darcy, & Paul A. Beavis. (2020). Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. Current Opinion in Pharmacology. 53. 91–97. 5 indexed citations

7.

Meyran, Déborah, Joe Jiang Zhu, Sean Macdonald, et al.. (2020). 126 Early-phenotype Lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1. SHILAP Revista de lepidopterología. A76.2–A78. 4 indexed citations

8.

House, Imran G., Peter Savas, Junyun Lai, et al.. (2019). Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research. 26(2). 487–504. 412 indexed citations breakdown →

9.

Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2018). Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research. 6(9). 1069–1081. 51 indexed citations

10.

Sek, Kevin, Christina Mølck, Gregory D. Stewart, et al.. (2018). Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. International Journal of Molecular Sciences. 19(12). 3837–3837. 144 indexed citations

11.

Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2017). Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation. 127(3). 929–941. 259 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact